Presented by:
Julie Kanter, MD
University of Alabama, Birmingham
Faculty Disclosure: Julie Kanter, MD has disclosed that she is a consultant for Novartis, Graphite Bio, Fulcrum Tx, and Forma Tx, and is on the Advisory Board for Magenta, Novartis, Beam, and Forma. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.
Release Date: May 27, 2022
Expiration Date: May 26, 2023
Target Audience: Primary Care Physicians, Specialty Physicians, Physician Assistants, Nurses, Pharmacists
Learning Objectives:
As a result of participation in this activity, participants should be able to:
- Learners will review the pathophysiology of sickle cell disease
- Audience will assess the challenges in transition of care in SCD
- Learners will understand how to mitigate some of the challenges for individuals with SCD
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resource(s) for further study:
- Br J Haematol.2012 Nov;159(3):360-7. doi: 10.1111/bjh.12024. Epub 2012 Sep 12.
- Mehari A, Alam S, Tian X, et al. HAm J Respir Crit Care Med. 2013;187 (8):840-847.
- Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ.. JAMA. 2012;307(12):1254-1256
- Brandow et al. Blood Adv (2020) 4 (12): 2656–2701
For additional information, contact Debbie Ringdahl at 352-273-9120 or e-mail ringdd@shands.ufl.edu.
Section #: 1816